Fluvastatin Inhibits Matrix Metalloproteinase-1 Expression in Human Vascular Endothelial Cells

Matrix metalloproteinase-1 (MMP-1), also called interstitial collagenase, may play an important role in the pathogenesis of atherosclerosis and atherosclerotic plaque rupture. We investigated the effects of fluvastatin on MMP-1 expression in human vascular endothelial cells (ECs). The addition of fluvastatin decreased the basal MMP-1 levels in the culture media of ECs in a time-dependent (0 to 48 hours) and dose-dependent (10−8 to 10−5 mol/L) manner. On the other hand, fluvastatin did not affect tissue inhibitor of metalloproteinase-1 levels. Collagenolytic activity in conditioned media of ECs was also dose-dependently reduced by fluvastatin. The effect of fluvastatin on MMP-1 expression was completely reversed in the presence of mevalonate or geranylgeranyl-pyrophosphate, but not in the presence of squalene. Inhibition of Rho by C3 exoenzyme also significantly decreased MMP-1 expression in ECs. Our findings revealed that fluvastatin decreases MMP-1 expression in human vascular ECs through inhibition of Rho.

[1]  A. Michael,et al.  Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. , 2003, British journal of clinical pharmacology.

[2]  F. Bernini,et al.  HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[3]  R. Roman,et al.  Lovastatin reduces renal vascular reactivity in spontaneously hypertensive rats. , 1998, American journal of hypertension.

[4]  A. Henney,et al.  Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. , 1998, Clinical science.

[5]  O. Eickelberg,et al.  Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection. , 1997, International journal of cardiology.

[6]  J. Pickering,et al.  Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells. Evidence for repressed collagen production and activated degradative capacity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[7]  S. Sebti,et al.  Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity , 1997, Oncogene.

[8]  Y. Kusumi,et al.  Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. , 1996, European journal of pharmacology.

[9]  S. Shapiro,et al.  Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Ferguson,et al.  Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. , 1995, Circulation.

[11]  F. Bernini,et al.  Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. , 1995, The American journal of cardiology.

[12]  P. Libby Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[13]  U. Ikeda,et al.  Suppressive role of endogenous endothelial monocyte chemoattractant protein-1 on monocyte transendothelial migration in vitro. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[14]  KazuyukiShimada,et al.  Suppressive Role of Endogenous Endothelial Monocyte Chemoattractant Protein–1 on Monocyte Transendothelial Migration In Vitro , 1995 .

[15]  S. Yap,et al.  Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. , 1995, Biochimica et biophysica acta.

[16]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[17]  E. Lakatta,et al.  Increased expression of 72 kDa type IV collagenase (MMP-2) in human atherosclerotic lesions , 1994 .

[18]  M. Rekhter,et al.  Cell proliferation and collagen synthesis are two independent events in human atherosclerotic plaques. , 1994, Journal of vascular research.

[19]  P. Libby,et al.  Enhanced Expression of Vascular Matrix Metalloproteinases Induced In Vitro by Cytokines and in Regions of Human Atherosclerotic Lesions a , 1994, Annals of the New York Academy of Sciences.

[20]  P. Heinrich,et al.  Regulation of tissue inhibitor of metalloproteinases‐1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures , 1993, Hepatology.

[21]  F. Bernini,et al.  Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. , 1993, Atherosclerosis.

[22]  M A Schork,et al.  Type I collagen gene expression in human atherosclerosis. Localization to specific plaque regions. , 1993, The American journal of pathology.

[23]  G. Gabbiani,et al.  Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. , 1993, Atherosclerosis.

[24]  E. Donetti,et al.  HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[25]  F. Tse,et al.  Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers , 1992, Journal of clinical pharmacology.

[26]  E. Lakatta,et al.  Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. , 1996, The American journal of pathology.

[27]  D H Blankenhorn,et al.  A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1992, Circulation.

[28]  S. Glagov,et al.  A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.